Latest news with #operatingexpenses
Yahoo
7 days ago
- Business
- Yahoo
Anterix Inc (ATEX) Q4 2025 Earnings Call Highlights: Strong Cash Position and Strategic Growth ...
Contracted Proceeds: $116 million from spectrum sales agreements with Encore and LCRA. Milestone Payments: $44 million from Encore and $8.5 million from Amin. Additional Cash Received: $34 million from accelerated spectrum delivery. Cash Position: Over $47 million in cash at the end of Q4 FY25. Outstanding Contracted Proceeds: Approximately $150 million, with $80 million expected in fiscal '26. Operating Expense Reduction: $4 million reduction in operating expense run rate from the first half of fiscal '25. Debt: No debt reported. Warning! GuruFocus has detected 2 Warning Signs with ATEX. Release Date: June 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Anterix Inc (NASDAQ:ATEX) has successfully optimized its cost structure, resulting in a $4 million reduction in operating expenses, enhancing efficiency and cash flow. The company is oversubscribed on its $250 million accelerator program, indicating strong demand for its 900 megahertz LTE spectrum. Anterix Inc (NASDAQ:ATEX) has no debt and closed the fourth quarter with over $47 million in cash, providing a strong financial position. The company has contracted spectrum covering 93% of Texas counties, creating a replicable regional deployment model nationwide. Anterix Inc (NASDAQ:ATEX) has approximately $150 million in outstanding contracted proceeds, with $80 million expected in fiscal '26, providing clear visibility and confidence in future cash flow. The strategic review process led by Morgan Stanley is ongoing with no predetermined outcome, creating uncertainty about future strategic directions. There is potential competition from other spectrum choices, such as the 800 megahertz band, which could impact Anterix Inc (NASDAQ:ATEX)'s market position. The company's market cap is currently low, which may affect its ability to leverage financial markets for growth. The transition to a 5x5 megahertz offering is still in progress, which may delay some potential customers who require this capability. Despite strong demand, the utility industry's typically slow decision-making process could delay the realization of new contracts and revenue. Q: Can you provide more details on the oversubscription of the $250 million accelerator program? Are there multiple players involved, and how are customers approaching this? A: Scott Lang, CEO: We are very pleased with the response to the accelerator program, with over a dozen utilities participating. The demand for private LTE 900 megahertz is strong, and negotiations are active. The utilities are engaged and in discussions, which is remarkable progress for the utility industry within a single quarter. Q: Have utilities begun engaging with partners as part of the accelerator program? A: Scott Lang, CEO: Yes, other companies have participated in the program. Ryan Gerbrandt, COO, added that partners like Ericsson, Nokia, and GE have joined, offering bespoke products to support and accelerate utilities' decision-making processes. Q: How might the 5x5 megahertz opportunity affect utilities' decisions to join the program, especially if they require it for their launch? A: Scott Lang, CEO: Utilities have not hesitated to join with the current 3x3 offering, which is sufficient for their needs. They are excited about the 5x5 plan, which enhances their confidence in the current offering's capabilities. Q: What is the strategy if Grain Management acquires 800 megahertz spectrum and targets utilities in regions where you have spectrum? A: Scott Lang, CEO: We are confident in our position with 900 megahertz, proven deployments, and strong economics. While 800 megahertz could be an alternative, we believe we will remain the preferred choice for utilities due to our comprehensive offerings and market leadership. Q: Do you have a goal for how much you would like to add to your contracted proceeds in the next 12 to 18 months? A: Timothy Gray, CFO: Our internal goals are to grow from the $116 million achieved last year, our best year yet. We believe the accelerator program will help us achieve significant growth in contract proceeds, although we are not providing specific numbers. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
28-05-2025
- Business
- Yahoo
Rakon Ltd (NZSE:RAK) Full Year 2025 Earnings Call Highlights: Navigating Challenges with ...
Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rakon Ltd (NZSE:RAK) achieved a significant reduction in operating expenses, down approximately 10% year on year, which helped preserve earnings despite challenging market conditions. The aerospace and defense segment delivered record revenue with double-digit year-on-year growth, continuing a positive trend for the last three years. There was a strong pick-up in telecommunications order volumes in the second half of the year, indicating stabilizing market conditions and selective global 5G investments. Rakon Ltd (NZSE:RAK) successfully reduced inventory by $8.5 million, releasing additional cash and improving working capital management. The company made significant strides in expanding into high-growth areas such as AI and cloud computing infrastructure, positioning itself for future revenue growth. FY25 revenue was down 19% year on year, reflecting tough conditions in core telecommunications and positioning markets. Rakon Ltd (NZSE:RAK) posted a net loss after tax of $5.8 million, including $3.6 million in one-off restructuring and transaction costs. The telecommunications segment faced a 33% year-on-year revenue decline due to continued demand weakness and inventory overhang at customers. Positioning revenue decreased by 21% from the prior year, with market weakness leading to lower order volumes. Gross margin percentage decreased to 43.1% due to loss of efficiencies from low production levels and fixed costs. Warning! GuruFocus has detected 4 Warning Signs with NZSE:RAK. Q: Can you talk to the level of working capital and if this new level is sustainable? A: Yes, we believe it is sustainable. As the business grows, receivables and payables will increase. Our key focus is on controlling inventory, and we have initiatives to review our inventory policies at various sites to maintain this level of working capital. (Respondent: CFO, Mark Dunwoody) Q: With net cash at the end of the year around $3 million, where do you expect this to be over FY26? A: We are working hard to return to a positive operating cash flow and are forecasting an improved cash position by the end of FY26. (Respondent: CFO, Mark Dunwoody) Q: On R&D, a large proportion of second-half spend was capitalized. Can you explain more on this and what will happen to this mix in FY26? A: Our technology teams are constantly working on new products, and we expect similar capitalization progress as we meet the IS 38 criteria during FY26. This is part of our strategy to turn R&D spending into assets for the company. (Respondent: CFO, Mark Dunwoody and CEO, Senan Oto) Q: Can you comment on the level of R&D likely to be expensed in FY26? A: We anticipate R&D expenses to be around $5 to $6 million next year, depending on the progress of our pipeline products. Our intention is to continue investing in R&D to maintain our technology leadership. (Respondent: CFO, Mark Dunwoody and CEO, Senan Oto) Q: Regarding your capital allocation priorities over the next year or two, do you expect to prioritize debt reduction, dividends, share buybacks, or reinvest in growth? A: We will continue to reinvest in growth, which remains a key focus. However, the exact strategy for capital allocation, including debt reduction, dividends, or share buybacks, has not yet been finalized with the board. (Respondent: CEO, Senan Oto) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Fountain Asset Corp. Announces Its Financial Results for the Quarter Ended March 31, 2025
TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Fountain Asset Corp. (TSXV:FA) ('Fountain' or the 'Company') would like to announce its financial results for the three months ended March 31, 2025 (' Q1/25 '). Highlights from Q1 2025: NAV of $5.57 million ($0.09/share) at March 31, 2025 compared to $5.51 million ($0.09/share) at December 31, 2024, representing a 1.0% increase on a quarter over quarter per share basis; Net comprehensive income of $0.05 million compared to net comprehensive losses of $0.45 million for the quarter ended March 31, 2024 (' Q1/24 '); Total gains from investment activity was $0.39 million compared to losses of $0.28 million for Q1/24; Net realized gains on the sale of portfolio investments of $1.29 million compared to net realized losses of $0.32 million for Q1/24; Net unrealized losses on portfolio investments of $0.96 million compared to net unrealized gains of $0.04 million for Q1/24; Total expenses of $0.34 million compared to $0.17 million for Q1/24; and Operating expenses of $0.16 million compared to $0.17 million for Q1/24. During Q1/25, the Company realized $1.29 million in gains on the sale of certain portfolio investments. The company saw a slight decrease in its portfolio of publicly traded companies as a result of the disposition of its holdings of certain investments. These decreases were offset by increases in the Company's new investment recent investments. The Company continued to find ways to reduce its operating expenses in Q1/25, which contributed to the profitability of the Company in Q1/25. As at March 31, 2025, the Company's net assets were valued at $5.57 million or $0.09 per share compared to $5.51 million or $0.09 per share at December 31, 2024. Andrew Parks, CEO of Fountain stated, 'During Q1/25, Fountain made meaningful progress toward its growth-oriented goals, generating significant realized gains. This strong start to the year strengthens the Company's financial position as it continues to realign its investment portfolio in order to capitalize on market trends and strategic opportunities. Fountian remains committed to reducing its ongoing expenditures while maximizing revenues to unlock the Company's full potential.' A full set of the Q1 2025 unaudited financial statements and the management discussion & analysis are available on SEDAR+. About Fountain Asset Corp. Fountain Asset Corp. is a merchant bank which provides equity financing, bridge loan services (asset back/collateralized financing) and strategic financial consulting services to companies across many industries such as marijuana, oil & gas, mining, real estate, manufacturing, retail, financial services, and biotechnology. Forward-Looking Statements Certain information contained in this press release constitutes forward-looking information, which is information relating to possible events, conditions or results of operations of the Company, which are based on assumptions and courses of action and which are inherently uncertain. All information other than statements of historical fact may be forward-looking information. Forward-looking information in this press release includes, but is not limited to, growing Fountain's capital base and a strong pipeline going forward. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: the level of bridge loans and equity investments completed, the nature and credit quality of the collateral security and the nature and quality of equity investments, and the other risks disclosed under the heading "Risk Factors" and elsewhere in the Company's annual information form dated August 17, 2022 filed on SEDAR+ at Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information: please contact Andrew Parks at (416) 456-7019 or visit Fountain Asset Corp.'s website at
Yahoo
26-05-2025
- Business
- Yahoo
Kadestone Capital Corp. Reports Q1 2025 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - Kadestone Capital Corp. (TSXV: KDSX) (OTCQB: KDCCF) ("Kadestone" or the "Company"), a vertically integrated property company today announced its financial results for the three months ended March 31, 2025. Financial Results For the three months ended March 31, 2025, the Company reported a net loss of $858,756, or $0.02 per share, compared to a net loss of $1,103,796, or $0.02 per share, for the same period in the prior year. The decreased loss was primarily driven by operating expenses including salaries and wages of $460,155, consulting fees of $458,083 and interest expense of $257,354. These expenses were partially offset by income from associates totaling $423,704 and income from an investment in a mortgage fund amounting to $115,146. Net cash used in operating activities also increased, rising to $1,700,161 for the three months ended March 31, 2025, compared to $966,500 in the prior year, reflecting the higher level of operational spending during the period. The above unaudited financial information, including comparative information, is expressed in Canadian dollars and has been prepared in accordance with IFRS Accounting Standards, using the accounting policies and methods of application as described in notes 2 and 3 of the Company's audited consolidated financial statements for the years ended December 31, 2024, and 2023. About Attollo Management Inc. Attollo Management Inc. is a private real estate development and management firm founded by David Negrin. The company specializes in urban redevelopment projects and is committed to building strong partnerships with Indigenous communities to deliver sustainable, community-driven developments. About Kadestone Kadestone was established to pursue the investment in, acquisition, development and management of residential and commercial income producing properties, and procurement and sale of building materials within major urban centres and high-growth, emerging markets in Canada. The Company operates five complimentary business lines spanning building materials procurement and supply, property development and construction, construction finance, asset ownership and property management. These synergistic business lines have solidified Kadestone's vision to become a market leading vertically integrated property company. Additional information can be found at For further information please contact David Negus, CFO, Kadestone Capital Corp., dnegus@ 604 671-8142 ON BEHALF OF THE BOARD (signed) "Brent Billey" President, CEO and Director Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward- Looking Statements Certain information in this press release, including, but not limited to, the Company's ability to identify opportunities and secure additional investments in 2025 and the Company's vision to become a leading vertically integrated property company, may constitute forward looking information (collectively, "forward-looking statements"), which can be identified by the use of terms such as "may," "will," "should," "expect," "anticipate," "project," "estimate," "intend," "continue" or "believe" (or the negatives) or other similar variations. Because of various risks and uncertainties, including those referenced below, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. As a result, you should not rely on such forward-looking statements. Additional information identifying assumptions, risks and uncertainties relating to Kadestone is contained in Kadestone's filings with the Canadian securities regulators available at These risks include those described in the "Risk Factors" section of the Company's final prospectus dated September 2, 2020, and in the Management's Discussion and Analysis for the years ended December 31, 2024 and 2023. The forward-looking statements in this press release are applicable only as of the date of this release or as of the date specified in the relevant forward-looking statement. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit
Yahoo
17-05-2025
- Business
- Yahoo
Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Total Revenue: $8.6 million for Q1 2025, a 9% increase from the same period in 2024. Ameluz Sales Increase: $0.5 million increase due to higher unit price and RotoLED XL lamp launch. Total Operating Expenses: $13.1 million for Q1 2025, down from $13.4 million in Q1 2024. Cost of Revenues: $3.1 million for Q1 2025, a 22.1% decrease from the prior year. SG&A Expenses: Decreased by $0.6 million or 6.5% compared to Q1 2024. R&D Expenses: Increased by $1.2 million due to assumption of clinical trial activities for Ameluz. Net Loss: $4.2 million or $0.47 per share for Q1 2025, compared to $10.4 million or $2.88 per share in Q1 2024. Adjusted EBITDA: Increased to $4.4 million for Q1 2025 from $4.6 million in Q1 2024. Cash and Cash Equivalents: $1.8 million as of March 31, 2025, down from $5.9 million as of December 31, 2024. Inventory: $6.5 million as of March 31, 2025, compared to $6.6 million as of December 31, 2024. Warning! GuruFocus has detected 5 Warning Signs with BFRI. Release Date: May 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Biofrontera Inc (NASDAQ:BFRI) reported a 9% increase in total revenues for the first quarter of 2025, reaching $8.6 million. The company successfully reduced its cost of revenue and operating costs compared to the same period in the previous year. A new formulation of Ameluz, free from the allergen propylene glycol, has been granted a patent, providing protection until December 2043. Biofrontera Inc (NASDAQ:BFRI) achieved key milestones in clinical trials, including the final patient enrollment for a Phase 3 trial of Ameluz for actinic keratosis and completion of a one-year follow-up for basal cell carcinoma treatment. The company increased its EBITDA and gross profit, supporting its goal of reaching breakeven quickly. Biofrontera Inc (NASDAQ:BFRI) reported a net loss of $4.2 million for the first quarter of 2025, although this was an improvement from the previous year's loss. The company experienced a decrease in cash and cash equivalents, dropping to $1.8 million as of March 31, 2025, from $5.9 million at the end of 2024. Research and development expenses increased by $1.2 million compared to the previous year, driven by the assumption of all clinical trial activities for Ameluz in the United States. Legal expenses increased by $1.2 million due to patent claims, partially offsetting savings in other areas. The sales force experienced some turnover, and the company is working on restructuring its commercial team to improve efficiency. Q: Over the first quarter of 2025, how many lamp units did Biofrontera sell, both the original and the XL? A: Herman Louvert, CEO, stated that Biofrontera placed 18 XL lamps during the first quarter. Clyde Lefler, CFO, mentioned that he would need to double-check the number of original lamps sold as he did not have that information readily available. Q: Is there any sales force attrition, and what is the current sales force headcount compared to the end of the year? A: Clyde Lefler, CFO, explained that Biofrontera is restructuring its commercial team, bringing in more junior representatives with lower salaries. There has been some turnover, but the company is committed to reorganizing the team to be as efficient as possible. Q: How will the change in transfer pricing affect gross margins for the rest of the year? A: Clyde Lefler, CFO, noted that all current inventory is at the 25% transfer price, which will be consistent for the rest of the year. However, gross margins may fluctuate based on the number of lamps sold, as the margin on lamps is lower. Q: What is the status of reimbursement for the three-tube indication? A: Herman Louvert, CEO, confirmed that after approval, Biofrontera focused on ensuring Medicare coverage and informed private payers. There have been no reported cases of reimbursement refusal for using more than one tube, indicating the issue is resolved. Q: Can you provide an update on the financial performance and strategic goals for the first quarter of 2025? A: Herman Louvert, CEO, highlighted that Biofrontera achieved a 9% revenue increase to $8.6 million, reduced costs, and improved EBITDA and gross profit. The company aims to reach breakeven quickly and continues to explore new applications for Ameluz, including treatments for superficial basal cell carcinoma and moderate to severe acne. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
